Background: The vascular disrupting agent combretastatin-A4-phosphate (CA4P) demonstrated antitumour activity in preclinical studies when combined with radiation.
introduction
The vascular disrupting agent combretastatin-A4-phosphate (CA4P) is a tubulin-binding agent that has potent activity in preventing tubulin polymerisation and microtubule assembly. Although the exact mechanism for the anti-vascular effects of CA4P remains under investigation, preclinical evidence suggests that it may be a consequence of endothelial cell shape changes and cell damage [1, 2] .
Phase I clinical trials of CA4P have demonstrated significant but transient reductions in tumour perfusion at a range of doses from 52 mg/m 2 up to the maximum tolerated dose of 68 mg/m 2 [3] [4] [5] [6] . However, despite evidence of tumour antivascular activity, there were minimal objective tumour responses in these trials. In preclinical studies, CA4P appears to selectively disrupt the vasculature in the tumour centre resulting in hemorrhagic necrosis, while leaving a rim of viable tumour cells at the periphery that can revascularise and proliferate [7] [8] [9] . This rim of surviving cells is thought to be a consequence of the shared normal vessel circulation between the perimeter of tumours and neighbouring normal tissue. This viable tumour rim might also be the result of circulating endothelial progenitor cells, which home to the rim following CA4P treatment [10] . In addition, the difference in interstitial fluid pressure and vascular architecture between the rim and the centre of the tumour may explain the catastrophic vascular shutdown that is observed following increase in permeability after CA4P [11] . These findings might therefore explain the lack of objective tumour response and partial recovery of perfusion when used as a single agent in phase I clinical trials. These findings suggest that in order to optimise the therapeutic effects of CA4P, it needs to be combined with another treatment modality that can target the surviving tumour rim.
CA4P, when combined with radiotherapy, as well as with chemotherapy, immunoradiotherapy, or antiangiogenic drugs, has been shown to enhance tumour control in vivo in preclinical studies [12] [13] [14] [15] . Recently, a completed phase II trial combining CA4P with carboplatin and paclitaxel demonstrated high response rates in heavily pretreated patients with ovarian epithelial cancer [16] . Radiotherapy is known to be effective at the tumour rim where blood flow and oxygenation is relatively normal [17] . Thus, combining CA4P with radiotherapy could provide the potential synergy that is required to treat the whole tumour.
The objective of this phase Ib trial was to determine the safety and toxicity profile of CA4P in combination with radiotherapy in patients with non-small-cell lung cancer (NSCLC), prostate adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN). To our knowledge, this is the first clinical trial combining CA4P with radiotherapy in patients with cancer.
patients and methods
Institutional ethical approval was obtained and signed informed consent was taken from all patients. Eligible patients had histologically confirmed NSCLC, prostate adenocarcinoma, and SCCHN. NSCLC patients were ineligible for resection with stage III and IV disease and, were unsuitable for radical radiotherapy and planned to be treated with palliative radiotherapy alone. Prostate cancer patients were locally advanced, as defined by a prostatespecific antigen (PSA) level >20, Gleason score of ‡7, or stage T3 or T4. Patients with head and neck squamous cell cancers had locally advanced tumours, stage III or IV.
Inclusion criteria included age ‡18 years, World Health Organization performance status of zero to two, life expectancy of >12 weeks, minimum 4-week interval between prior chemotherapy, immunotherapy, and radiotherapy and receiving CA4P, and adequate renal, hepatic, and haematological function. Patients were excluded if they had major surgery in the preceding 4 weeks, active brain metastases, grade 2 or greater peripheral neuropathy, clinically significant cardiac abnormality including uncontrolled hypertension, history of angina or myocardial infarction, arrhythmias, prolongation of QTc interval, symptomatic peripheral vascular disease or cerebrovascular disease.
study design
This was a single-centre dose escalation study, designed to assess the safety and tolerability of radiotherapy in combination with CA4P. Patients were recruited into cohorts of six patients receiving one of three radiotherapy schedules. Patients with NSCLC received 27 Gy in 6 fractions treating twice weekly, patients with prostate adenocarcinoma received 55 Gy in 20 fractions treating daily over 4 weeks, and patients with SCCHN received 66 Gy in 33 fractions treating daily over 6 weeks. These were standard schedules in use at Mount Vernon Cancer Centre at the time of this study. Each successive cohort of patients within each radiotherapy schedule had an increase in exposure to CA4P from one dose, to three doses (once a week for 3 weeks), to six doses (either twice a week for 3 weeks, or once weekly for 6 weeks). CA4P dose was escalated from 50 mg/m 2 to 63 mg/m 2 . The dose escalation schedule is summarised in Table 1 . In addition, patients with intermediaterisk prostate cancer received 6 months of antiandrogen therapy, while patients with high-risk prostate cancer received 3 years of adjuvant antiandrogen therapy, and patients with SCCHN received cetuximab at the standard doses in combination with radiotherapy and CA4P.
treatment and dose escalation
Palliative NSCLC radiotherapy used anterior and posterior opposed 6 MV photon beams defined on a treatment simulator with the prescription dose defined at the midplane of the field centre; no formal dosimetry was carried out for these patients. Prostate volumes were defined using computerised tomography (CT) datasets. The Clinical Target Volume (CTV) included the prostate capsule and seminal vesicles with a CTV to Planning Target Volume (PTV) expansion of 10 mm in all planes except posteriorly where this was reduced to 5 mm. Three or four field conformal plans using 6-10 MV photons were used with formal planning constraints for dose to the rectum such that the total dose to 30% is <57 Gy, 50% is <52 Gy, and 60% is <43 Gy. Head and neck patients were all treated with immobilisation shells and volumes were defined using CT datasets. The CTV was defined by the individual Gross Tumour Volume (GTV) with clinically relevant regional node areas and the CTV to PTV expansion was 5 mm. Two, three, or four field conformal plans using 6-10 MV photons were used and the maximum dose to the spinal cord was constrained to <44 Gy.
The CA4P dose corresponds to the weight of the free acid, which is equal to 90% of the dose representing the disodium salt. Thus 50 mg/m 2 of CA4P as the free acid is equivalent to a dose of 55.5 mg/m 2 of the disodium salt, which is higher than the threshold dose of 52 mg/m 2 that has been shown to have tumour anti-vascular activity as a single agent, and is below the dose-limiting toxicity (DLT). In all patients, CA4P was administered as a 10-min infusion, 2 h after receiving radiotherapy for that day. Patients were allowed to receive CA4P for the duration of the radiotherapy course only. Provided that no DLT occurred in two or more patients per cohort, doses of radiation or CA4P were increased as detailed in Table 1 . If the maximum tolerated regimen was identified in cohorts 1-4, the study would have ceased. If the maximum tolerated regimen was identified in cohort 5, recruitment into cohorts 6 and 7 would have been allowed but at the lower CA4P dose. A CA4P DLT was defined as QTc prolongation as evidenced by a QTc interval of ‡500 ms, grade 2 or greater ventricular arrhythmia (secondor third-degree atrio-ventricular block), severe sinus bradycardia <45 or tachycardia >120 not due to other causes (e.g. fever), persistent supraventricular arrhythmia lasting >24 h, ventricular tachycardia, or any length of torsades de pointes, or unexplained recurrent syncope, or any grade toxicity which required the removal of an individual patient from further treatment. The maximum tolerated regimen was defined as the highest combination of CA4P and radiotherapy at which no more than one patient experienced a DLT.
Patients were monitored for safety and toxicity. Toxic effects were recorded according to the National Cancer Institute-Common Toxicity Criteria version 2.0. The relationship of the adverse event to the drug treatment was scored as certainly, probably, possibly, unlikely, or unrelated. Baseline clinical examinations and haematological and biochemical blood tests, were carried out during the screening process and repeated before each cycle of CA4P. Three pre-dose 12-lead electrocardiographs (ECG) were carried out 5 min apart and the mean of the QTc measurements were recorded. Blood pressure, pulse rate, and ECG readings were measured before CA4P and repeated hourly for 6 h after CA4P. All ECGs were read locally by the investigator and by a consultant cardiologist based at the local tertiary cardiothoracic centre.
response assessment
For patients with NSCLC, tumour evaluations were carried out at baseline, and follow-up scans to assess response were carried out at 1, 3 and 6 months after completion of treatment. Criteria for response and progression were based on the RECIST. Patients with prostate adenocarcinoma were followed up with 3-6 monthly PSA measurements. Table 1 . Dose levels, dose escalations, and treatment schedule
C, CA4P treatment; CA4P, combretastatin-A4-phosphate; NSCLC, non-small-cell lung cancer; R, radiation treatment; SCCHN, squamous cell carcinoma of the head and neck.
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beats and first-degree atrioventricular block) before his first dose of CA4P, and was withdrawn from the study, leaving 39 assessable patients. Patient characteristics are listed in Table 2 .
toxic effects
Thirty-nine patients received 121 doses of CA4P. DLTs were reached with CA4P at a weekly dose of 63 mg/m 2 and at a weekly dose of 50 mg/m 2 in combination with cetuximab. There was no additional toxicity when CA4P was administered twice a week at a dose of 50 mg/m 2 in combination with radiotherapy. There was no radiotherapy-related DLT, and there was no enhancement of radiation toxicity with the addition of CA4P. Drug-related toxic effects are listed in Table 3 .
Five patients were unable to complete the study. One patient with SCCHN recruited on to the seventh treatment cohort missed the fourth of his six planned doses of CA4P because of a chest infection; the same patient subsequently had to be withdrawn from the study because of a fractured femur sustained after a fall that resulted in early death. Four patients were withdrawn because of DLT. One patient with prostate cancer treated in the fifth cohort with CA4P at a weekly dose of 63 mg/m 2 developed grade 3 ataxia within 24 h of his first dose of CA4P, which resolved spontaneously within a week. An MRI scan of his brain showed age-related small vessel disease only. CA4P was stopped and he went on to complete his radiation treatment after a delay of 1 week. A second patient treated in the same cohort developed grade 3 oculomotor nerve palsy about 2 h after his second dose of CA4P. An MRI scan of his brain carried out on the same day did not reveal any abnormalities, and his symptoms resolved within 24 h. CA4P was stopped and he went on to complete radiation treatment without delay. As per protocol, patients recruited into cohorts six and seven were therefore treated at the lower CA4P dose of 50 mg/m 2 ( Table 1) . Two patients in the seventh cohort with SCCHN treated with CA4P at a dose of 50 mg/m 2 weekly in combination with cetuximab developed grade 3 cardiac ischaemia, with raised cardiac troponins. The first patient experienced cardiac chest pain 2 h after the third dose of CA4P. The second patient developed grade 3 hypertension after the fourth dose of CA4P, followed shortly by cardiac chest pain. Both patients stopped CA4P and received standard medical treatment of acute coronary syndrome. Radiation treatment concurrent with cetuximab was resumed without delay. As a result of these two events, further recruitment into this cohort was halted, and the trial was stopped.
cardiac toxicity
Overall, 22 patients (56%) developed grade 1 or 2 hypertension. Three patients (8%) developed grade 3 hypertension; two of these patients had received CA4P at the higher dose of 63 mg/ m 2 . The third patient with SCCHN developed cardiac ischaemia as described above. In general, there was a significant increase in systolic blood pressure from a baseline of 128.4 mmHg to 150.8 mmHg at 1 h, an increase of 17.5% (P < 0.001) (Figure 1 ). This returned to baseline at 3 h after CA4P, followed by relative hypotension to 124.7 mmHg at 5 h, a decrease of 2.8% (P < 0.001). Similarly, diastolic blood pressure increased from a baseline of 74.5 mmHg to 85.7 mmHg at 1 h after CA4P, an increase of 15.0% (P < 0.001), returning to baseline at 3 h after CA4P. At 6 h, there was a small but significant decrease in diastolic blood pressure to 73.6 mmHg, a decrease of 1.3% (P = 0.006) compared with baseline. This was associated with a significant decrease in pulse rate from a baseline of 74.6 bpm to 66.3 bpm at 1 h after CA4P, a decrease of 11.2% (P < 0.001). This was followed by a relative tachycardia, which at 6 h was 82.8 bpm, an increase of 11.0% (P < 0.001). Fourteen patients (36%) developed either sinus bradycardia or tachycardia; all were grade 1.
Four patients (10%) developed prolonged QTc interval, all at grade 1 or 2. There was a small but significant decrease in QTc at 1 h after CA4P from a baseline of 419.9 ms to 409.0 ms, a decrease of 2.6% (P < 0.001). This was followed by an increase in QTc to 431.9 ms at 3 h, an increase of 2.9% (P < 0.001). At 6 h, QTc remained marginally but significantly prolonged at 431.0 ms, an increase of 2.7% (P < 0.001).
other toxicity
Tumour pain occurred in 12 of the 18 patients with NSCLC but none of the patients with prostate cancer or SCCHN. Haematological toxic effects observed included 25 patients with lymphopenia, of which 9 were grade 3 or 4. Two patients experienced leucopoenia and two had neutropenia, all were grade 1 or 2. Ten patients had hypophosphatemia, two were grade 3, and both patients had received CA4P at the higher dose of 63 mg/m 2 .
tumour response
Patients with NSCLC were evaluated for RECIST response. Two patients were not assessed for radiological response because of early deaths due to progressive disease. No complete responses were observed. Seven patients had partial responses, giving an overall response rate of 39%. Nine patients had stable disease. The 1-year survival was 39% and the median overall survival for the 18 patients was 10 months. All 18 patients with prostate cancer were followed up with regular PSA measurements. At 3 years, all patients were still alive. Three patients had biochemical relapse as defined by the Phoenix definition, one of which had metastatic nodal disease.
Four patients with SCCHN were treated. One patient developed metastatic disease 4 months after completion of treatment and went on to receive palliative chemotherapy. At 3 years, two of the remaining three patients had developed progressive disease and passed away. One patient remains disease free and on follow-up.
discussion
This phase Ib trial was planned such that each successive cohort of patients had either more total radiation exposure or more total CA4P exposure or both. By design therefore, we can accumulate toxicity data in several specific cancers under several fractionated radiotherapy regimens. The scheduling of CA4P, and the radiotherapy regimens used in this study, specifically considered data from preclinical studies, where the enhancement of CA4P by radiation appears to be dependent on timing and scheduling. In the C3H mammary carcinoma, improvement in tumour control was only observed when CA4P was administered at the same time as, or after radiation [14, 18] .
In the phase I trials of single-agent CA4P, functional imaging using dynamic contrast-enhanced magnetic resonance imaging, H 2 15 O-and C 15 O-positron emission tomography were used to demonstrate acute but transient reductions in tumour perfusion within 4 h, with partial recovery at 24 h after CA4P. Therefore, in this clinical study, patients received CA4P 2 h after radiotherapy; there was an interval of at least 48 h between administration of CA4P and the subsequent fraction of radiation to enable reoxygenation of residual tumour cells. The numbers represent the number of patients experiencing the toxicity. CTC, common terminology criteria for adverse events version 2.0; NSCLC, non-small-cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck.
Dose-limiting cardiac ischaemia was observed in two patients with SCCHN, when CA4P at a dose of 50 mg/m 2 was administered concurrently with cetuximab. In a phase II trial of cetuximab combined with chemotherapy concurrent with radiotherapy in patients with SCCHN, two unexpected and unexplained deaths were reported [19] . Another patient had a nonfatal myocardial infarction, and another developed sepsis and atrial fibrillation, complicated by hypotension. The authors suggested that the co-morbidities prevalent in the SCCHN population might have contributed to the increased incidence of adverse events. In our study, both patients who experienced dose-limiting cardiac ischaemia did not have any significant medical history and did not have any family history of cardiac disease. Furthermore, when cetuximab was combined with radiotherapy in a randomised phase III trial, there was no enhancement of radiation toxicity with the addition of cetuximab, and the number of early deaths in both arms of the trial was equivalent [20] . However, in patients with colorectal cancer, the addition of cetuximab or panitumumab to chemotherapy and the antiangiogenic agent bevacizumab was shown to confer a worse outcome, with increased toxic effects [21, 22] . Cetuximab is known to be an indirect inhibitor of angiogenesis [23, 24] ; this may have contributed to the enhanced toxic vascular effects when combined with CA4P. Pharmacokinetic interaction between cetuximab and CA4P is not known and was not tested in our study and is another possible reason for the two cardiac events observed. There is at present no clear explanation for this unexpected finding, and additional preclinical studies combining vascular disrupting agents with monoclonal antibodies to epidermal growth factor receptor will be needed before this combination can be recommended in future clinical trials.
Hypertension has been previously reported with CA4P. The increase in systolic and diastolic blood pressures is shown to correlate with increasing dose levels of CA4P in both human and animal models, and thought to be due to an increase in normal tissue vascular resistance [16, 25] . Hypertensive events are also well recognised following angiogenesis inhibition with both monoclonal antibodies and tyrosine kinase inhibitors [26] . In the current study, asymptomatic increases in systolic and diastolic blood pressures were observed. Three patients had grade 3 hypertension; two of these patients had received CA4P at the higher dose of 63 mg/m 2 . In the phase II trial of CA4P in combination with chemotherapy in patients with ovarian cancer, hypertension was easily controlled by sublingual or transdermal glyceryl trinitrate, and premedication with amlodipine [16] . More recently, a study in mice showed that the magnitude (but not durability) of the change in blood pressure was dose independent in the range between 10 and 250 mg/kg [27] . Furthermore, blood pressure correction does not appear to compromise treatment efficacy and administration of vasoactive agents may therefore be a safe means to reduce adverse effects and possibly increase the tolerable dose of CA4P. In a previous phase I study of CA4P, 18 of 24 patients developed prolongation of the QTc interval after CA4P [28] . In our study, patients with a prolonged QTc interval on pretreatment 12-lead ECG were excluded; consequently, only four patients developed grade 1 or 2 prolongation of the QTc interval.
DLTs of reversible ataxia and oculomotor nerve palsy were observed in two patients at a CA4P dose of 63 mg/m 2 . Similar DLTs were encountered in a phase I trial at doses of 88 mg/m 2 and 114 mg/m 2 [4] . Additional neurological effects, including transient paraesthesia and lower limb weakness, were reported in this and other phase I trials [5, 6] . Neurotoxicities are known complications of tubulin-binding agents, including taxanes and vinca alkaloids [29] , which probably reflect the tubulin-binding mechanism of CA4P. However, the underlying pathophysiologic mechanisms are not fully elucidated. Mean (695% confidence intervals) change in heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) following treatment with combretastatin-A4-phosphate (CA4P) for 39 patients. Measurements were taken before CA4P and repeated hourly for 6 h after each dose of CA4P.
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In conclusion, radiotherapy with CA4P appears well tolerated in the majority of patients. The combination of CA4P and cetuximab with radiotherapy needs further scrutiny before it can be recommended for clinical studies. The recommended phase II dose is once weekly CA4P at 50 mg/m 2 , in combination with radiotherapy up to a dose of 66 Gy.
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